IL274488B2 - Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide - Google Patents

Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Info

Publication number
IL274488B2
IL274488B2 IL274488A IL27448820A IL274488B2 IL 274488 B2 IL274488 B2 IL 274488B2 IL 274488 A IL274488 A IL 274488A IL 27448820 A IL27448820 A IL 27448820A IL 274488 B2 IL274488 B2 IL 274488B2
Authority
IL
Israel
Prior art keywords
crystalline form
composition
treating
thalassemia
angles
Prior art date
Application number
IL274488A
Other languages
English (en)
Hebrew (he)
Other versions
IL274488B1 (en
IL274488A (en
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64734113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL274488(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL274488A publication Critical patent/IL274488A/en
Publication of IL274488B1 publication Critical patent/IL274488B1/en
Publication of IL274488B2 publication Critical patent/IL274488B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL274488A 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide IL274488B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US201862691709P 2018-06-29 2018-06-29
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Publications (3)

Publication Number Publication Date
IL274488A IL274488A (en) 2020-06-30
IL274488B1 IL274488B1 (en) 2023-09-01
IL274488B2 true IL274488B2 (en) 2024-01-01

Family

ID=64734113

Family Applications (3)

Application Number Title Priority Date Filing Date
IL274488A IL274488B2 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
IL305343A IL305343B2 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
IL322576A IL322576A (en) 2017-11-22 2018-11-21 Crystalline forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL305343A IL305343B2 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
IL322576A IL322576A (en) 2017-11-22 2018-11-21 Crystalline forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Country Status (27)

Country Link
US (3) US11254652B2 (enExample)
EP (2) EP4285904A3 (enExample)
JP (2) JP7275130B2 (enExample)
KR (3) KR102682430B1 (enExample)
CN (2) CN117551030A (enExample)
AU (3) AU2018373122B2 (enExample)
BR (1) BR112020010185A2 (enExample)
CA (1) CA3081945A1 (enExample)
DK (1) DK3713919T3 (enExample)
ES (1) ES2959764T3 (enExample)
FI (1) FI3713919T3 (enExample)
HR (1) HRP20230931T1 (enExample)
HU (1) HUE063264T2 (enExample)
IL (3) IL274488B2 (enExample)
LT (1) LT3713919T (enExample)
MD (1) MD3713919T2 (enExample)
MX (2) MX2020005348A (enExample)
PH (1) PH12020550644A1 (enExample)
PL (1) PL3713919T3 (enExample)
PT (1) PT3713919T (enExample)
RS (1) RS64592B1 (enExample)
SG (1) SG11202004587XA (enExample)
SI (1) SI3713919T1 (enExample)
SM (1) SMT202300327T1 (enExample)
TW (2) TWI922809B (enExample)
UA (1) UA127502C2 (enExample)
WO (1) WO2019104134A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
JP2022533227A (ja) * 2019-05-22 2022-07-21 アジオス ファーマシューティカルズ， インコーポレイテッド Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性塩形態
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12286404B2 (en) * 2020-01-28 2025-04-29 Teva Pharmaceuticals International Gmbh Solid state forms of Mitapivat and process for preparation thereof
CN116568281A (zh) * 2020-09-25 2023-08-08 安吉奥斯医药品有限公司 药物制剂
CA3196829A1 (en) * 2020-09-25 2022-03-31 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
EP4329758A1 (en) 2021-04-30 2024-03-06 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2023154036A1 (en) * 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
KR20240107326A (ko) 2021-11-16 2024-07-09 아지오스 파마슈티컬스 아이엔씨. Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물
US20260146025A1 (en) 2022-10-17 2026-05-28 Tianish Laboratories Private Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos
WO2024228131A1 (en) * 2023-05-02 2024-11-07 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-quinoline sulfonamide, n-[4-[[4(cyclopropylmethyl)-1-piperazinyl] carbonyl] phenyl]-sulfate and its process for preparation thereof
WO2025008787A1 (en) * 2023-07-05 2025-01-09 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of mitapivat hemisulfate
WO2025083627A1 (en) * 2023-10-18 2025-04-24 Apitoria Pharma Private Limited Novel crystalline forms of mitapivat sulfate and processes for preparation
WO2025146636A1 (en) * 2024-01-03 2025-07-10 Tianish Laboratories Private Limited Novel crystalline polymorphs of mitapivat sulfate salt

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785450B2 (en) * 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
IN191496B (enExample) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
US20010041706A1 (en) 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
AU2001288690A1 (en) 2000-09-05 2002-03-22 Odyssey Pharmaceuticals Llc Two-component anti-emetic composition comprising dexamethasone and metoclopramide
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2008088895A2 (en) 2007-01-18 2008-07-24 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
US20140162942A1 (en) 2010-07-30 2014-06-12 Anima Ghosal Inhibition of cyp3a drug metabolism
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
EP2877214B1 (en) * 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
JP2017513921A (ja) 2014-03-03 2017-06-01 アーチャルジー、スジャータ ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785450B2 (en) * 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL.,, PHARMACEUTICALS SALTS, 1 January 1977 (1977-01-01) *
BYRN ET AL.,, PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS, 1 January 1995 (1995-01-01) *
CAIRA,, CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS, 1 January 1998 (1998-01-01) *

Also Published As

Publication number Publication date
AU2018373122B2 (en) 2023-11-09
EP3713919B1 (en) 2023-08-02
TWI922809B (zh) 2026-04-21
AU2018373122A1 (en) 2020-05-21
DK3713919T3 (da) 2023-09-25
KR20240108581A (ko) 2024-07-09
EP4285904A2 (en) 2023-12-06
CA3081945A1 (en) 2019-05-31
SG11202004587XA (en) 2020-06-29
IL274488B1 (en) 2023-09-01
KR20200090787A (ko) 2020-07-29
FI3713919T3 (fi) 2023-09-29
JP2023093762A (ja) 2023-07-04
US20200277279A1 (en) 2020-09-03
TWI808108B (zh) 2023-07-11
MD3713919T2 (ro) 2024-02-29
TW202334115A (zh) 2023-09-01
UA127502C2 (uk) 2023-09-13
MX2020005348A (es) 2020-08-13
ES2959764T3 (es) 2024-02-28
KR20250034202A (ko) 2025-03-10
IL305343A (en) 2023-10-01
LT3713919T (lt) 2023-10-10
SMT202300327T1 (it) 2023-11-13
KR102777452B1 (ko) 2025-03-10
EP4285904A3 (en) 2023-12-20
US20220220093A1 (en) 2022-07-14
US20260217676A1 (en) 2026-07-30
IL305343B2 (en) 2026-01-01
RS64592B1 (sr) 2023-10-31
CN111372920A (zh) 2020-07-03
US11254652B2 (en) 2022-02-22
MX2022009998A (es) 2022-09-19
AU2024200724A1 (en) 2024-02-22
TW201930289A (zh) 2019-08-01
JP2021504338A (ja) 2021-02-15
IL322576A (en) 2025-10-01
BR112020010185A2 (pt) 2021-01-12
EP3713919A1 (en) 2020-09-30
WO2019104134A1 (en) 2019-05-31
JP7275130B2 (ja) 2023-05-17
PT3713919T (pt) 2023-10-26
PL3713919T3 (pl) 2023-12-27
US12612381B2 (en) 2026-04-28
AU2024200724B2 (en) 2026-02-05
AU2026203244A1 (en) 2026-05-14
IL305343B1 (en) 2025-09-01
CN117551030A (zh) 2024-02-13
KR102682430B1 (ko) 2024-07-08
CN111372920B (zh) 2023-10-20
SI3713919T1 (sl) 2023-10-30
HRP20230931T1 (hr) 2023-11-24
HUE063264T2 (hu) 2024-01-28
IL274488A (en) 2020-06-30
PH12020550644A1 (en) 2021-04-26

Similar Documents

Publication Publication Date Title
FI3713919T3 (fi) N-(4-(4-(syklopropyylimetyyli)piperatsiini-1-karbonyyli)fenyyli)kinoliini-8-sulfonamidin kiteisiä muotoja
JP2021504338A5 (enExample)
EP4299135A3 (en) Benzisoxazole sulfonamide derivatives
FI3307271T3 (fi) Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
JP2018035160A5 (enExample)
FI3470063T3 (fi) Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon
ES2910003T3 (es) Compuestos y composiciones de cocristal iónico de litio de anión orgánico
JP2020532535A5 (enExample)
TWI739756B (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物
RU2015106137A (ru) Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
KR20090019914A (ko) 테가세로드를 단독으로 포함하거나 또는 양성자 펌프 억제제와 조합으로 포함하는, 위 손상의 치료 또는 예방용 조성물
WO2015199356A1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
JP2011527687A5 (enExample)
JP2024045113A5 (enExample)
MX2026001663A (es) Formulaciones farmaceuticas de agonistas de gpr119 y usos de estas
RU2016106336A (ru) Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения
HRP20250002T1 (hr) Ampreloksetin, namijenjen upotrebi u liječenju neurogene ortostatske hipotenzije
RU2009124593A (ru) Полиморфные формы деферасирокса (icl670a)
CA2728890C (en) Amide derivative-containing pharmaceutical composition
WO2008085674A1 (en) Pharmaceutical compositions comprising celecoxib co-crystals
NZ805778A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1- carbonyl)phenyl)quinoline-8-sulfonamide
TW201808296A (zh) 含有胺甲蝶呤之膜衣錠
JP2022533227A5 (enExample)
WO2013169218A1 (en) Pharmaceutical compositions of s-etodolac
JP2022184669A (ja) テネリグリプチン含有医薬組成物